Skip to main content

Table 2 Cumulative proportions of treatment success (adequate clinical and parasitological response) for each treatment arm at fixed time points in pregnant women

From: A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border

 

Cumulative percentage of treatment success (95% CI) estimated by Kaplan-Meier method

p value

DP

ASMQ

AL+

P. falciparum* PCR-corrected

N = 49

N = 55

N = 50

0.13

 Day 28

93.7% (81.6–97.9)

81.5% (68.4–89.6)

91.9% (79.8–96.9)

 

 Day 42

93.7% (81.6–97.9)

81.5% (68.4–89.6)

87.5% (74.3–94.2)

 

 Day 63

93.7% (81.6–97.9)

79.6% (66.1–88.1)

87.5% (74.3–94.2)

 

 Delivery

93.7% (81.6–97.9)

79.6% (66.1–88.1)

87.5% (74.3–94.2)

 

P. falciparum* PCR-uncorrected

N = 49

N = 57

N = 50

0.07

 Day 28

93.7% (81.6–97.9)

80.4% (67.4–88.6)

91.9% (79.8–96.9)

 

 Day 42

91.4% (78.7–96.7)

80.4% (67.4–88.6)

87.5% (74.3–94.2)

 

 Day 63

91.4% (78.7–96.7)

78.5% (65.3–87.2)

87.5% (74.3–94.2)

 

 Delivery

91.4% (78.7–96.7)

70.7% (53.8–82.4)

84.6% (70.2–92.4)

 

P. vivax*

N = 125

N = 117

N = 126

0.0006‡

 Day 28

100.0%

100.0%

95.8% (90.2–98.2)

 

 Day 42

98.3% (93.4–99.6)

99.0% (93.2–99.9)

79.3% (70.8–85.6)

 

 Day 63

82.9% (74.5–88.8)

89.5% (81.4–94.2)

68.5% (59.0–76.1)

 

 Delivery

20.6% (5.1–43.4)

46.0% (30.9–60.0)

28.7% (10.0–50.8)

 

Any malaria recurrence

N = 171

N = 169

N = 170

0.03‡

 Day 28

98.2% (94.6–99.4)

92.5% (87.2–95.7)

93.9% (88.9–96.6)

 

 Day 42

95.1% (90.4–97.5)

90.6% (84.8–94.2)

79.2% (72.0–84.7)

 

 Day 63

83.1% (76.1–88.2)

80.8% (73.4–86.2)

69.9% (62.0–76.4)

 

 Delivery

37.3% (18.7–56.0)

48.7% (37.3–59.2)

43.7% (26.5–59.7)

 
  1. AL+ artemether-lumefantrine extended regimen, ASMQ artesunate-mefloquine, CI confidence interval, DP dihydroartemisinin-piperaquine, PCR polymerase chain reaction
  2. *Including co-infection of P. falciparum and P. vivax
  3. p values by log-rank test or Wilcoxon test (‡). For all endpoints, + 3 days allowed